TY  - GEN
AU  - Scherpereel,Arnaud
AU  - Mazieres,Julien
AU  - Greillier,Laurent
AU  - Lantuejoul,Sylvie
AU  - Dô,Pascal
AU  - Bylicki,Olivier
AU  - Monnet,Isabelle
AU  - Corre,Romain
AU  - Audigier-Valette,Clarisse
AU  - Locatelli-Sanchez,Myriam
AU  - Molinier,Olivier
AU  - Guisier,Florian
AU  - Urban,Thierry
AU  - Ligeza-Poisson,Catherine
AU  - Planchard,David
AU  - Amour,Elodie
AU  - Morin,Franck
AU  - Moro-Sibilot,Denis
AU  - Zalcman,Gérard
TI  - Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
SN  - 1474-5488
PY  - 2020///0611
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Female
KW  - Humans
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Male
KW  - Mesothelioma
KW  - Mesothelioma, Malignant
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
KW  - Pleural Neoplasms
KW  - Prospective Studies
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(18)30765-4
ER  -